Literature DB >> 25361945

Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective.

Leslie A Andritsos1, Neil Dunavin2, Gerard Lozanski3, Jeffrey A Jones4, James S Blachly4, David M Lucas4, John C Byrd4, Eric Kraut4, Michael R Grever4.   

Abstract

Entities:  

Keywords:  hairy cell leukemia; pentostatin

Mesh：

Substances：

Year:  2014        PMID： 25361945      PMCID： PMC4281329          DOI： 10.3324/haematol.2014.113290

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Leukemic reticuloendotheliosis.

Authors:  B A BOURONCLE; B K WISEMAN; C A DOAN
Journal:  Blood       Date:  1958-07       Impact factor: 22.113

2.  Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial.

Authors:  Tadeusz Robak; Krzysztof Jamroziak; Joanna Gora-Tybor; Jerzy Z Blonski; Marek Kasznicki; Jadwiga Dwilewicz-Trojaczek; Elzbieta Wiater; Andrzej Zdunczyk; Jacek Dybowicz; Anna Dmoszynska; Maria Wojtaszko; Barbara Zdziarska; Malgorzata Calbecka; Aleksandra Kostyra; Andrzej Hellmann; Krzysztof Lewandowski; Beata Stella-Holowiecka; Kazimierz Sulek; Krzysztof Gawronski; Aleksander B Skotnicki; Wieslaw Nowak; Krystyna Zawilska; Lucyna Molendowicz-Portala; Janusz Kloczko; Jaroslaw Sokolowski; Krzysztof Warzocha; Ilona Seferynska; Bernardeta Ceglarek; Lech Konopka
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

3.  Pentostatin in the treatment of advanced hairy cell leukemia.

Authors:  E H Kraut; B A Bouroncle; M R Grever
Journal:  J Clin Oncol       Date:  1989-02       Impact factor: 44.544

4.  Long-term follow-up of patients with hairy cell leukemia after cladribine treatment.

Authors:  A Saven; C Burian; J A Koziol; L D Piro
Journal:  Blood       Date:  1998-09-15       Impact factor: 22.113

Review 5.  Long-term results for pentostatin and cladribine treatment of hairy cell leukemia.

Authors:  Claire E Dearden; Monica Else; Daniel Catovsky
Journal:  Leuk Lymphoma       Date:  2011-06

6.  Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study.

Authors:  M Grever; K Kopecky; M K Foucar; D Head; J M Bennett; R E Hutchison; W E Corbett; P A Cassileth; T Habermann; H Golomb
Journal:  J Clin Oncol       Date:  1995-04       Impact factor: 44.544

Review 7.  How I treat hairy cell leukemia.

Authors:  Michael R Grever
Journal:  Blood       Date:  2009-10-20       Impact factor: 22.113

Review 8.  Long-term follow-up studies in hairy cell leukemia.

Authors:  Michael R Grever; Pier Luigi Zinzani
Journal:  Leuk Lymphoma       Date:  2009-10

9.  Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98).

Authors:  R Zenhäusern; S-F Hsu Schmitz; M Solenthaler; D Heim; S Meyer-Monard; U Hess; L Leoncini; M Bargetzi; B Rufener; A Tobler
Journal:  Leuk Lymphoma       Date:  2009-09

10.  Risk factors for severe infection in patients with hairy cell leukemia: a long-term study of 73 patients.

Authors:  Ghandi Damaj; Frédérique Kuhnowski; Jean-Pierre Marolleau; Francis Bauters; Xavier Leleu; Ibrahim Yakoub-Agha
Journal:  Eur J Haematol       Date:  2009-03-19       Impact factor: 2.997
View more
  2 in total

1.  Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.

Authors:  Michael R Grever; Omar Abdel-Wahab; Leslie A Andritsos; Versha Banerji; Jacqueline Barrientos; James S Blachly; Timothy G Call; Daniel Catovsky; Claire Dearden; Judit Demeter; Monica Else; Francesco Forconi; Alessandro Gozzetti; Anthony D Ho; James B Johnston; Jeffrey Jones; Gunnar Juliusson; Eric Kraut; Robert J Kreitman; Loree Larratt; Francesco Lauria; Gerard Lozanski; Emili Montserrat; Sameer A Parikh; Jae H Park; Aaron Polliack; Graeme R Quest; Kanti R Rai; Farhad Ravandi; Tadeusz Robak; Alan Saven; John F Seymour; Tamar Tadmor; Martin S Tallman; Constantine Tam; Enrico Tiacci; Xavier Troussard; Clive S Zent; Thorsten Zenz; Pier Luigi Zinzani; Brunangelo Falini
Journal:  Blood       Date:  2016-11-30       Impact factor: 22.113

2.  Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays.

Authors:  Yash Gupta; Dawid Maciorowski; Samantha E Zak; Krysten A Jones; Rahul S Kathayat; Saara-Anne Azizi; Raman Mathur; Catherine M Pearce; David J Ilc; Hamza Husein; Andrew S Herbert; Ajay Bharti; Brijesh Rathi; Ravi Durvasula; Daniel P Becker; Bryan C Dickinson; John M Dye; Prakasha Kempaiah
Journal:  Methods       Date:  2021-01-14       Impact factor: 3.608
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.